Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8296 to 8310 of 8944 results

  1. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued Reference number: GID-TA10144

    Technology appraisal guidance
    Discontinued

  2. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued Reference number: GID-TA10148

    Technology appraisal guidance
    Discontinued

  3. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued Reference number: GID-TA10149

    Technology appraisal guidance
    Discontinued

  4. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued Reference number: GID-TA10151

    Technology appraisal guidance
    Discontinued

  5. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued Reference number: GID-TA10154

    Technology appraisal guidance
    Discontinued

  6. Peramivir for treating influenza [ID828]

    Discontinued Reference number: GID-TA10155

    Technology appraisal guidance
    Discontinued

  7. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued Reference number: GID-TA10157

    Technology appraisal guidance
    Discontinued

  8. Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

    Discontinued Reference number: GID-TA10158

    Technology appraisal guidance
    Discontinued

  9. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued Reference number: GID-TAG444

    Technology appraisal guidance
    Discontinued

  10. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  11. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  12. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  13. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  14. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  15. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued Reference number: GID-TAG494

    Technology appraisal guidance
    Discontinued